141 related articles for article (PubMed ID: 19546757)
41. Genital and nongenital teratogenesis of prenatal progestogen therapy: the effects of 17 alpha-hydroxyprogesterone caproate on embryonic and fetal development and endochondral ossification in the C57B1/6J mouse.
Carbone JP; Brent RL
Am J Obstet Gynecol; 1993 Nov; 169(5):1292-8. PubMed ID: 8238197
[TBL] [Abstract][Full Text] [Related]
42. Transplacental transfer and metabolism of 17-alpha-hydroxyprogesterone caproate.
Hemauer SJ; Yan R; Patrikeeva SL; Mattison DR; Hankins GD; Ahmed MS; Nanovskaya TN
Am J Obstet Gynecol; 2008 Aug; 199(2):169.e1-5. PubMed ID: 18674659
[TBL] [Abstract][Full Text] [Related]
43. Progestogens for the prevention of preterm birth and risk of developing gestational diabetes mellitus: a meta-analysis.
Pergialiotis V; Bellos I; Hatziagelaki E; Antsaklis A; Loutradis D; Daskalakis G
Am J Obstet Gynecol; 2019 Nov; 221(5):429-436.e5. PubMed ID: 31132340
[TBL] [Abstract][Full Text] [Related]
44. Does progesterone treatment influence risk factors for recurrent preterm delivery?
Meis PJ; Klebanoff M; Dombrowski MP; Sibai BM; Leindecker S; Moawad AH; Northen A; Iams JD; Varner MW; Caritis SN; O'Sullivan MJ; Miodovnik M; Leveno KJ; Conway D; Wapner RJ; Carpenter M; Mercer B; Ramin SM; Thorp JM; Peaceman AM; Gabbe S
Obstet Gynecol; 2005 Sep; 106(3):557-61. PubMed ID: 16135587
[TBL] [Abstract][Full Text] [Related]
45. 17α Hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Merlob P; Stahl B; Klinger G
Reprod Toxicol; 2012 Jan; 33(1):15-9. PubMed ID: 22120850
[TBL] [Abstract][Full Text] [Related]
46. Outcomes With Cerclage Alone Compared With Cerclage Plus 17α-Hydroxyprogesterone Caproate.
Berghella V; Owen J; Szychowski JM
Obstet Gynecol; 2017 Feb; 129(2):390-391. PubMed ID: 28121824
[No Abstract] [Full Text] [Related]
47. Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins.
Attardi BJ; Zeleznik A; Simhan H; Chiao JP; Mattison DR; Caritis SN;
Am J Obstet Gynecol; 2007 Dec; 197(6):599.e1-7. PubMed ID: 18060946
[TBL] [Abstract][Full Text] [Related]
48. 17-Hydroxyprogesterone caproate (17OHP-C) coverage among eligible women delivering at 2 North Carolina hospitals in 2012 and 2013: A retrospective cohort study.
Stringer EM; Vladutiu CJ; Manuck T; Verbiest S; Ollendorff A; Stringer JS; Menard MK
Am J Obstet Gynecol; 2016 Jul; 215(1):105.e1-105.e12. PubMed ID: 26829508
[TBL] [Abstract][Full Text] [Related]
49. Meta-analysis of randomized controlled trials comparing 17α-hydroxyprogesterone caproate and vaginal progesterone for the prevention of recurrent spontaneous preterm delivery.
Oler E; Eke AC; Hesson A
Int J Gynaecol Obstet; 2017 Jul; 138(1):12-16. PubMed ID: 28369874
[TBL] [Abstract][Full Text] [Related]
50. Population pharmacokinetics of 17α-hydroxyprogesterone caproate in singleton gestation.
Sharma S; Caritis S; Hankins G; Miodovnik M; Hebert MF; Mattison D; Venkataramanan R
Br J Clin Pharmacol; 2016 Oct; 82(4):1084-93. PubMed ID: 27133963
[TBL] [Abstract][Full Text] [Related]
51. Regional differences in utilization of 17α-hydroxyprogesterone caproate (17-OHP).
Hart JM; Hakim JB; Wylie BJ; Beam AL
J Perinat Med; 2022 Nov; 50(9):1203-1209. PubMed ID: 35654442
[TBL] [Abstract][Full Text] [Related]
52. Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial.
Price JT; Vwalika B; Freeman BL; Cole SR; Mulenga HB; Winston J; Mbewe FM; Chomba E; Mofenson LM; Rouse DJ; Goldenberg RL; Stringer JSA
BMC Pregnancy Childbirth; 2019 Feb; 19(1):81. PubMed ID: 30813934
[TBL] [Abstract][Full Text] [Related]
53. [Characteristics of oral glucose tolerance test in 9803 pregnant women of different pre-pregnancy body mass index and its relationship with the incidence of gestational diabetes mellitus].
Wei Y; Guo Q; Sun W; Yang H
Zhonghua Fu Chan Ke Za Zhi; 2015 Nov; 50(11):830-3. PubMed ID: 26887770
[TBL] [Abstract][Full Text] [Related]
54. Effect of 17alpha-hydroxyprogesterone caproate before embryo transfer on the outcome of in vitro fertilization and embryo transfer: a randomized trial.
Abu-Musa A; Usta I; Nassar A; Hajami F; Hannoun A
Fertil Steril; 2008 May; 89(5):1098-1102. PubMed ID: 17658525
[TBL] [Abstract][Full Text] [Related]
55. Unjustified increase in cost of care resulting from U.S. Food and Drug Administration approval of Makena (17α-hydroxyprogesterone caproate).
Cohen AW; Copel JA; Macones GA; Menard MK; Riley L; Saade GR
Obstet Gynecol; 2011 Jun; 117(6):1408-1412. PubMed ID: 21471853
[TBL] [Abstract][Full Text] [Related]
56. Does gestational diabetes affect fetal growth and pregnancy outcome in twin pregnancies?
Tward C; Barrett J; Berger H; Kibel M; Pittini A; Halperin I; Cohen H; Melamed N
Am J Obstet Gynecol; 2016 May; 214(5):653.e1-8. PubMed ID: 26596233
[TBL] [Abstract][Full Text] [Related]
57. Does 17-alpha hydroxyprogesterone caproate prevent recurrent preterm birth in obese women?
Heyborne KD; Allshouse AA; Carey JC
Am J Obstet Gynecol; 2015 Dec; 213(6):844.e1-6. PubMed ID: 26275354
[TBL] [Abstract][Full Text] [Related]
58. Early postpartum metabolic assessment in women with prior gestational diabetes.
Pallardo F; Herranz L; Garcia-Ingelmo T; Grande C; Martin-Vaquero P; Jañez M; Gonzalez A
Diabetes Care; 1999 Jul; 22(7):1053-8. PubMed ID: 10388966
[TBL] [Abstract][Full Text] [Related]
59. 17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going?
Manuck TA
Semin Perinatol; 2017 Dec; 41(8):461-467. PubMed ID: 28947068
[TBL] [Abstract][Full Text] [Related]
60. A prospective randomized study comparing intramuscular progesterone and 17alpha-hydroxyprogesterone caproate in patients undergoing in vitro fertilization-embryo transfer cycles.
Costabile L; Gerli S; Manna C; Rossetti D; Di Renzo GC; Unfer V
Fertil Steril; 2001 Aug; 76(2):394-6. PubMed ID: 11476795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
